These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 22261804)

  • 1. Phase I dose-escalation study of intravenous aflibercept in combination with docetaxel in patients with advanced solid tumors.
    Isambert N; Freyer G; Zanetta S; You B; Fumoleau P; Falandry C; Favier L; Assadourian S; Soussan-Lazard K; Ziti-Ljajic S; Trillet-Lenoir V
    Clin Cancer Res; 2012 Mar; 18(6):1743-50. PubMed ID: 22261804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I Dose-Escalation and Pharmacokinetic Study of Intravenous Aflibercept in Combination with Docetaxel, Cisplatin, and 5-Fluorouracil in Patients with Advanced Solid Malignancies.
    Bahleda R; Baker J; Massard C; Gadgeel SM; Rogers JE; Izzedine H; Deutsch E; Garris JL; Khan A; Boelle E; Assadourian S; Soria JC; Ajani JA
    Oncology; 2016; 90(1):10-20. PubMed ID: 26492090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours.
    Freyer G; Isambert N; You B; Zanetta S; Falandry C; Favier L; Trillet-Lenoir V; Assadourian S; Soussan-Lazard K; Ziti-Ljajic S; Fumoleau P
    Br J Cancer; 2012 Aug; 107(4):598-603. PubMed ID: 22790797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours.
    Van Cutsem E; Khayat D; Verslype C; Billemont B; Tejpar S; Meric JB; Soussan-Lazard K; Assadourian S; Cartot-Cotton S; Rixe O
    Eur J Cancer; 2013 Jan; 49(1):17-24. PubMed ID: 22921183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer.
    Coleman RL; Duska LR; Ramirez PT; Heymach JV; Kamat AA; Modesitt SC; Schmeler KM; Iyer RB; Garcia ME; Miller DL; Jackson EF; Ng CS; Kundra V; Jaffe R; Sood AK
    Lancet Oncol; 2011 Nov; 12(12):1109-17. PubMed ID: 21992853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial.
    Ramlau R; Gorbunova V; Ciuleanu TE; Novello S; Ozguroglu M; Goksel T; Baldotto C; Bennouna J; Shepherd FA; Le-Guennec S; Rey A; Miller V; Thatcher N; Scagliotti G
    J Clin Oncol; 2012 Oct; 30(29):3640-7. PubMed ID: 22965962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A dose escalation study of weekly docetaxel in patients with advanced solid tumors.
    Kouroussis C; Agelaki S; Mavroudis D; Souglakos J; Kakolyris S; Kalbakis K; Vardakis N; Reppa D; Hatzidaki D; Samonis G; Georgoulias V
    Cancer Chemother Pharmacol; 2000; 46(6):488-92. PubMed ID: 11138462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Docetaxel, ifosfamide and cisplatin in solid tumour treatment: a phase I study.
    Specenier P; Rasschaert M; Van den Brande J; Dyck J; Schrijvers D; Huizing MT; Vermorken JB
    Anticancer Drugs; 2010 Mar; 21(3):306-12. PubMed ID: 20087171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I dose-escalation study of the safety, tolerability, and pharmacokinetics of aflibercept in combination with S-1 in Japanese patients with advanced solid malignancies.
    Doi T; Boku N; Onozawa Y; Takahashi K; Kawaguchi O; Ohtsu A
    Invest New Drugs; 2020 Oct; 38(5):1390-1399. PubMed ID: 31907738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours.
    Awada A; Hendlisz A; Christensen O; Lathia CD; Bartholomeus S; Lebrun F; de Valeriola D; Brendel E; Radtke M; Delaunoit T; Piccart-Gebhart M; Gil T
    Eur J Cancer; 2012 Mar; 48(4):465-74. PubMed ID: 22285181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer.
    LoRusso PM; Jones SF; Koch KM; Arya N; Fleming RA; Loftiss J; Pandite L; Gadgeel S; Weber BL; Burris HA
    J Clin Oncol; 2008 Jun; 26(18):3051-6. PubMed ID: 18565892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I study of bi-weekly docetaxel for recurrent or advanced gastric cancer patients whose disease progressed by prior chemotherapy.
    Kimura Y; Yano H; Taniguchi H; Iwazawa T; Danno K; Kagara N; Kanoh T; Ohnishi T; Tono T; Nakano Y; Monden T; Imaoka S
    Jpn J Clin Oncol; 2011 Jun; 41(6):747-51. PubMed ID: 21498408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer.
    Sym SJ; Ryu MH; Kang HJ; Lee SS; Chang HM; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):373-80. PubMed ID: 19936751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours.
    Diaz-Padilla I; Siu LL; San Pedro-Salcedo M; Razak AR; Colevas AD; Shepherd FA; Leighl NB; Neal JW; Thibault A; Liu L; Lisano J; Gao B; Lawson EB; Wakelee HA
    Br J Cancer; 2012 Aug; 107(4):604-11. PubMed ID: 22805331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies.
    Posey JA; Wang H; Hamilton J; Delgrosso A; Zhang R; Freda T; Zamboni WC
    Cancer Chemother Pharmacol; 2005 Aug; 56(2):182-8. PubMed ID: 15838660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumors.
    Garland LL; Hidalgo M; Mendelson DS; Ryan DP; Arun BK; Lovalvo JL; Eiseman IA; Olson SC; Lenehan PF; Eder JP
    Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4274-82. PubMed ID: 16857802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumors.
    Van Den Neste E; de Valeriola D; Kerger J; Bleiberg H; Kusenda Z; Brassinne C; Bartholomeus S; Selleslags J; Hennebert P; Wythouck H; Cazenave I; Lefresne-Soulas F; Piccart M
    Clin Cancer Res; 2000 Jan; 6(1):64-71. PubMed ID: 10656433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours: results from the expansion cohort of a phase I study.
    Khayat D; Tejpar S; Spano JP; Verslype C; Bloch J; Vandecaveye V; Assadourian S; Soussan-Lazard K; Cartot-Coton S; Van Cutsem E
    Eur J Cancer; 2013 Mar; 49(4):790-7. PubMed ID: 23312881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of combination therapy with S-1 and docetaxel (TXT) for advanced or recurrent gastric cancer.
    Yoshida K; Hirabayashi N; Takiyama W; Ninomiya M; Takakura N; Sakamoto J; Nishiyama M; Toge T
    Anticancer Res; 2004; 24(3b):1843-51. PubMed ID: 15274365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blind, placebo-controlled study to assess QTc interval prolongation of standard dose aflibercept in cancer patients treated with docetaxel.
    Maison-Blanche P; Vermorken JB; Goksel T; Machiels JP; Agarwala S; Rottey S; Daugaard G; Volovat C; Scheulen M; Sengeløv L; Grecea D; Eniu A; Jäger E; Meiri E; Cascinu S; Strumberg D; Demir G; Clemens M; Pinotti G; Nardi M; Guthrie T; Boelle E; Magherini E
    J Cardiovasc Pharmacol; 2013 Jun; 61(6):495-504. PubMed ID: 23429593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.